Immunomedics, Inc. (IMMU) Earns “Outperform” Rating from Cowen and Company

Immunomedics, Inc. (NASDAQ:IMMU)‘s stock had its “outperform” rating reissued by stock analysts at Cowen and Company in a research note issued on Monday, July 24th. They currently have a $15.00 target price on the biopharmaceutical company’s stock. Cowen and Company’s price objective suggests a potential upside of 92.31% from the stock’s previous close.

IMMU has been the subject of several other reports. Zacks Investment Research raised Immunomedics from a “sell” rating to a “buy” rating and set a $9.50 price objective for the company in a research note on Tuesday, July 11th. Wells Fargo & Company raised Immunomedics from a “market perform” rating to an “outperform” rating in a research note on Friday, May 5th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Immunomedics in a research note on Friday, July 14th. Finally, ValuEngine raised Immunomedics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $12.00.

Shares of Immunomedics (NASDAQ:IMMU) traded up 0.78% during mid-day trading on Monday, hitting $7.80. The company had a trading volume of 1,972,298 shares. The firm’s market capitalization is $854.91 million. The firm has a 50-day moving average price of $8.59 and a 200 day moving average price of $6.79. Immunomedics has a 12 month low of $2.02 and a 12 month high of $9.51.

ILLEGAL ACTIVITY WARNING: “Immunomedics, Inc. (IMMU) Earns “Outperform” Rating from Cowen and Company” was published by Stock Observer and is the sole property of of Stock Observer. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.thestockobserver.com/2017/08/12/immunomedics-inc-immu-stock-rating-reaffirmed-by-cowen-and-company-updated-updated.html.

Institutional investors have recently added to or reduced their stakes in the company. EAM Investors LLC increased its position in Immunomedics by 270.1% in the second quarter. EAM Investors LLC now owns 507,114 shares of the biopharmaceutical company’s stock valued at $4,478,000 after buying an additional 370,086 shares during the last quarter. Parametric Portfolio Associates LLC increased its position in Immunomedics by 67.4% in the second quarter. Parametric Portfolio Associates LLC now owns 279,713 shares of the biopharmaceutical company’s stock valued at $2,470,000 after buying an additional 112,636 shares during the last quarter. FMR LLC increased its position in Immunomedics by 260.6% in the second quarter. FMR LLC now owns 5,496,851 shares of the biopharmaceutical company’s stock valued at $48,537,000 after buying an additional 3,972,388 shares during the last quarter. Vanguard Group Inc. increased its position in Immunomedics by 2.4% in the second quarter. Vanguard Group Inc. now owns 4,522,091 shares of the biopharmaceutical company’s stock valued at $39,930,000 after buying an additional 105,558 shares during the last quarter. Finally, Northern Trust Corp increased its position in Immunomedics by 2.5% in the second quarter. Northern Trust Corp now owns 1,276,821 shares of the biopharmaceutical company’s stock valued at $11,275,000 after buying an additional 30,926 shares during the last quarter. 62.10% of the stock is owned by institutional investors.

Immunomedics Company Profile

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Receive News & Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply